Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 2,409 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Invasive Procedure Clear all

Conditions: Bladder Cancer, Muscle Invasive Bladder Cancer
Interventions: Avelumab, Radiation; Drug · Radiation
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions: ravuconazole; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diffuse Intrinsic Pontine Glioma, Diffuse Pontine and Thalamic Gliomas, Diffuse Midline Glioma, H3 K27M-Mutant
Interventions: Panobinostat 15 MG, Focused Ultrasound with neuro-navigator-controlled sonication; Drug · Device
Lead sponsor: Columbia University; Other
Eligibility: 4 Years to 21 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Superficial Bladder Cancer
Interventions: Chemophase; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 5
States / cities: Phoenix, Arizona • Anaheim, California • La Mesa, California + 2 more

Conditions: Heart Transplantation
Interventions: Magnetocardiograph; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Acute Respiratory Failure, Acute on Chronic Respiratory Failure, Dyspnea
Interventions: NIV, CPAP, Standard oxygen, HFNC; Device
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Various Advanced Cancer
Interventions: Nivolumab, Placebo; Biological · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 709 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 33
States / cities: Anchorage, Alaska • Tucson, Arizona • Clovis, California + 27 more

Conditions: Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC), Urothelial Carcinoma, Carcinoma in Situ (CIS), High-Grade Papillary Bladder Tumors, BCG-Unresponsive Bladder Cancer, Ta Stage Bladder Cancer, T1 Stage Bladder Cancer, BCG-Refractory Bladder Cancer, High-Risk NMIBC, Micropapillary Variant Urothelial Carcinoma (Favorable Subtype)
Interventions: Intravesical Gemcitabine and Docetaxel; Drug
Lead sponsor: Michael A. O'Donnell; Other
Eligibility: 18 Years to 99 Years
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Bladder Cancer
Interventions: Apaziquone, Placebo; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 7
States / cities: Los Angeles, California • Miami, Florida • Somerville, New Jersey + 4 more

Conditions: Hydrocephalus
Interventions: ShuntCheck test; Device
Lead sponsor: NeuroDx Development; Industry
Eligibility: 35 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Depression, Breast Cancer, Stress, Breast Cancer Non-invasive Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Breast Cancer Metastatic Breast Cancer
Interventions: Videoconferencing support group; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Body Fat Disorder
Interventions: The Zeltiq CoolSculpting System; Device
Lead sponsor: Zeltiq Aesthetics; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Pleasanton, California

Conditions: Pulmonary Invasive Fungal Infections, Pulmonary Invasive Aspergillosis
Interventions: Non-Invasive Testing for PIFI; Diagnostic Test
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 120 Days to 21 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 32
States / cities: Little Rock, Arkansas • La Jolla, California • Orange, California + 28 more

Conditions: Breast Cancer
Interventions: Visica 2™ Treatment System, Cryoablation, Surgical Resection; Device · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Invasive Breast Carcinoma
Interventions: Biospecimen Collection, Educational Intervention, Extended Release Metformin Hydrochloride, Questionnaire Administration; Procedure · Other · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 3
States / cities: Duarte, California • La Jolla, California • Riverside, California

Conditions: Anal Squamous Cell Carcinoma, HIV Infection, Stage 0 Anal Canal Cancer, Stage I Anal Canal Cancer
Interventions: Therapeutic Conventional Surgery; Procedure
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 5
States / cities: San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 2 more

Conditions: Reversal of Coagulopathy
Interventions: Beriplex® P/N (Kcentra), Fresh frozen plasma; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 16
States / cities: Newark, Delaware • Lexington, Kentucky • Boston, Massachusetts + 13 more

Conditions: PTSD, Depression
Interventions: NEST-1, SHAM, NEST-2; Device
Lead sponsor: Providence VA Medical Center; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Providence, Rhode Island • White River Junction, Vermont

Conditions: Pediatric Invasive Candidiasis
Interventions: Observational antifungal therapy; Drug
Lead sponsor: Duke University; Other
Eligibility: 120 Days to 18 Years
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 27
States / cities: Little Rock, Arkansas • Orange, California • Palo Alto, California + 24 more

Conditions: Breast Cancer
Interventions: brachytherapy; Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 216
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 167 more

Conditions: Ocular Hypertension
Interventions: ST266 via Intranasal Delivery; Combination Product
Lead sponsor: Noveome Biotherapeutics, formerly Stemnion; Industry
Eligibility: 20 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Colorectal Cancer
Interventions: Accelerated Recovery Plan, Early Discharge, Telemedicine, Standard Enhanced Care; Behavioral · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 79 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cosmetic Techniques
Interventions: Onabotulinumtoxina for Injection, Abobotulinumtoxina for Injection, IncobotulinumtoxinA for Injection, PrabotulinumtoxinA for Injection; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 30 Years to 65 Years · Female only
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Tobacco Use Disorder
Interventions: active tDCS, sham tDCS; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 64 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

Avelumab and Radiation in Muscle-Invasive Bladder Cancer

Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation

Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG)

Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder Cancer

Magnetocardiography as a Non-Invasive Tool for Detecting Tissue Rejection in Heart Transplant Patients

Treatment of Dyspnea in Do-not-intubate Patients

An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)

ShuntCheck Versus Radionuclide in Evaluating Shunt Function in Symptomatic NPH Patients

Expanding Rural Access: Distance Delivery of Support Groups (Main Study)

Fat Layer Reduction in the Lateral Thighs Using CoolSculpting

Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections

Cryoablation for Invasive Breast Carcinoma Following Neoadjuvant Therapy

Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy

Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection

An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N (Kcentra) Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure

Synchronized Transcranial Magnetic Stimulation for PTSD

PEACE: Pediatric Antifungal Comparative Effectiveness

Radiation Therapy in Treating Women With Stage I or Stage II Breast Cancer

Study of ST266 Given by Intranasal Delivery in Glaucoma Suspect Subjects

Accelerated Enhanced RECOVERy Following Minimally Invasive Colorectal Cancer Surgery (RecoverMI)

Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella Area

Effect of a Non-Invasive Brain Stimulation Technique on Smoking Cessation Behaviors